Drug-based cancer therapy to overcome immune resistance by steering tumor evolution | ||
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur | |
| dc.contributor.author | Fernandez, Ariel | |
| dc.date.issued | 2019-01 | |
| dc.description.abstract | We argue that therapy must lead rather than follow vis-à-vis cancer evolution. Clinical experience suggests that the evading phenotype resulting from treatment can never be fully anticipated or eliminated when a single source of selection pressure is applied during treatment. Thus, therapy must steer cancer evolution and LIC may well become the underlying paradigm to overcome resistance in a therapeutic context where immune surveillance is maintained. | es |
| dc.description.fil | Fil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Fernandez, Ariel; Drug-based cancer therapy to overcome immune resistance by steering tumor evolution; Informa Healthcare; Expert Opinion On Drug Discovery; 14; 1; 1-2019; 5-8 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1746-0441 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/151968 | |
| dc.journal.ciudad | Londres | es |
| dc.journal.number | 1 | es |
| dc.journal.pagination | 5-8 | es |
| dc.journal.pais | Reino Unido | es |
| dc.journal.title | Expert Opinion On Drug Discovery | es |
| dc.journal.volume | 14 | es |
| dc.language.iso | eng | es |
| dc.publisher | Informa Healthcare | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1550066 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/17460441.2019.1550066 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | CANCER EVOLUTION | es |
| dc.subject | CANCER RESISTANCE | es |
| dc.subject | IMMUNE CHECKPOINT INHIBITOR | es |
| dc.subject | IMMUNE EVASION | es |
| dc.subject | PHOSPHOINOSITIDE-3 KINASE INHIBITOR | es |
| dc.subject | TARGETED THERAPY | es |
| dc.subject.classification | Tecnologías que involucran la manipulación de células, tejidos, órganos o todo el organismo | es |
| dc.subject.classification | Biotecnología de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Drug-based cancer therapy to overcome immune resistance by steering tumor evolution | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.8cfd5505-6ca2-4dd6-be64-3788e946c00d_A.pdf
- Tamaño:
- 940.23 KB
- Formato:
- Adobe Portable Document Format